- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02803593
To Enhance Breast Cancer Survivorship of Asian Americans (TICAA)
28. juni 2022 oppdatert av: Eun-Ok Im, Emory University
The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
Despite few studies on Asian American breast cancer survivors, it is well known that these women shoulder unnecessary burden of breast cancer because they rarely complain about symptoms or pain, delay seeking help, and rarely ask or get support due to their cultural values and beliefs and language barriers.
This demonstrates a definite need for support in this specific population.
However, survivorship programs that are increasingly instituted at cancer centers have serious impediments to providing information and coaching/support because of the lack of staff time and insurance reimbursement.
Furthermore, the pressure of fast-paced clinical patient-provider interactions leaves little time for health care providers to provide up-to-date information and coaching or support for these women based on their cultural attitudes.
All these circumstances necessitate an innovative and creative delivery method of information and coaching/support.
A technology-based approach using computers and mobile devices (smart phones and tablets) promises to meet this necessity with high flexibility and accessibility, and minimizes the cost of the intervention in busy and costly health care settings.
Also, a technology-based intervention that does not involve face-to-face interactions could work better for many women from cultures where breast cancer is still a stigmatizing experience.
Therefore, based on preliminary studies, the research team has developed and pilot-tested a theory-driven technology-based information and coaching/support program that is culturally tailored to Asian American breast cancer survivors using multiple features.
The purpose of the proposed randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.
The specific aims are to: a) determine whether the intervention group will show significantly greater improvements than the control group in primary outcomes (needs for help, physical and psychological symptoms, and quality of life) from baseline (pre-test) to Time Points 1 (post 1-month) and 2 (post 3-months); b) identify theory-based variables (attitudes, self-efficacy, perceived barriers, and social influences related to breast cancer survivorship) that mediate the intervention effects of the TICAA on the primary outcomes at the three time points (pre-test, post 1-month and post 3-months); and c) determine whether the effects of the TICAA on the primary outcomes are moderated by background characteristics and disease factors.
The proposed study will be guided by the Bandura's Theory of Behavioral Change.
This study adopts a randomized repeated measures pretest/posttest control group design in 330 Asian American breast cancer survivors.
The long-term goals are to: (a) implement the program into various health care settings; (b) determine if the TICAA will lead to long-term improved health outcomes; and (c) fundamentally enhance the methodology/paradigm of culturally tailored technology-based interventions for ethnic minority groups of breast cancer survivors.
Studietype
Intervensjonell
Registrering (Faktiske)
199
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Emory University Hospital
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke University, School of Nursing
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
21 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- Self-reported Asian American women aged 21 years and older who identify their sub-ethnicity as Chinese, Korean, or Japanese
- Have had a breast cancer diagnosis
- Can read and write English, Mandarin Chinese, Korean or Japanese
- Have access to the Internet through computers or mobile devices (smart phones and tablets)
Exclusion Criteria:
- Those under 21 years old are excluded because their cancer experience would be different from adults
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Control
Asian American breast cancer survivors who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS).
Participants are asked to use the online ACS resources for 3 months.
|
The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
|
Eksperimentell: TICAA Intervention
Asian American breast cancer survivors who use the TICAA intervention and the information by the ACS.
The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors.
Participants are asked to use the TICAA program for 3 months.
|
The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources.
The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers.
The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship.
The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Support Care Needs Survey (SCNS) Score
Tidsramme: Baseline, Month 1, Month 3
|
The SCNS uses 57 items to measure how much help the respondent needs.
Responses are given on a scale from 1 to 5 where 1 = no help is needed and 5 = high need for help.
Total scores range from 57 to 285 and higher scores indicate greater need for help.
|
Baseline, Month 1, Month 3
|
Memorial Symptom Assessment Scale-Short Form (MSAS-SF) Score
Tidsramme: Baseline, Month 1, Month 3
|
Physical and psychological symptoms are assessed using the Memorial Symptom Assessment Scale-Short Form (MSAS-SF).
The MSAS-SF asks if the respondent has experienced any of 32 specific symptoms during the past week, with the opportunity for the participant to enter additional symptoms.
The degree of distress experienced by 28 of the symptoms is measured on a scale from 0 (not at all) to 4 (very much).
The total score is the average of the responses to the distress scale items and and ranges from 0 to 4 with higher values indicating greater distress experienced from symptoms.
|
Baseline, Month 1, Month 3
|
Functional Assessment of Cancer Therapy Scale-Breast Cancer (FACT-B) Score
Tidsramme: Baseline, Month 1, Month 3
|
Quality of life is assessed using the FACT-B.
The FACT-B includes 41 items which are responded to on a scale from 0 to 4, where 0 = not at all and 4 = very much.
The total score ranges from 0 to 164 and higher scores indicate better quality of life.
|
Baseline, Month 1, Month 3
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Attitudes
Tidsramme: Baseline, Month 1, Month 3
|
Attitudes related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Attitudes section of this questionnaire includes 6 items scaled from -3 to 3, where -3 is the most negative score and 3 is the most positive score.
There are also 7 qualitative questions.
The total score for the scaled items ranges from -18 to 18 and higher scores indicate a better attitude towards breast cancer survivorship.
|
Baseline, Month 1, Month 3
|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Perceived Barriers
Tidsramme: Baseline, Month 1, Month 3
|
Perceived barriers related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Perceived Barriers section of this questionnaire includes 16 items where responses are given on a 4-point scale where 1 = never and 4 = always.
Total scores range from 16 to 64 and higher scores indicate greater perceived barriers related to breast cancer survivorship.
|
Baseline, Month 1, Month 3
|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Social Influences
Tidsramme: Baseline, Month 1, Month 3
|
Social influences related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Social Influences section of this questionnaire includes 3 items where responses are given on a 7-point scale where 1 = disapproval from social support and 7 = approval from social support.
Total scores range from 3 to 21 and higher scores indicate greater positive support from social influences.
|
Baseline, Month 1, Month 3
|
Cancer Behavior Inventory-Brief Version (CBI-B) Score
Tidsramme: Baseline, Month 1, Month 3
|
Self-efficacy related to breast cancer survivorship is measured using the Cancer Behavior Inventory-Brief Version (CBI-B).
The CBI-B has 12 items assessing the degree of confidence respondents have with certain coping behaviors on a scale from 1 (not at all confident) to 9 (totally confident).
Total scores range from 12 to 108 where higher scores indicate greater self-efficacy concerning cancer behaviors.
|
Baseline, Month 1, Month 3
|
Personal Resource Questionnaire (PRQ-2000) Score
Tidsramme: Baseline, Month 1, Month 3
|
The Personal Resource Questionnaire (PRQ-2000) is a 15-item survey asking how much participants agree or disagree with statements related to social resources on a scale from 1 (strongly disagree) to 7 (strongly agree).
Total scores range from 15 to 105 and higher scores indicate greater social resources.
|
Baseline, Month 1, Month 3
|
Perceived Isolation Scale (PIS) Score
Tidsramme: Baseline, Month 1, Month 3
|
The Perceived Isolation Scale (PIS) includes 9 items asking questions about how social connectedness.
Responses are rated on a 3-point scale where 1 = hardly ever, 2 = some of the time, and 3 = often.
The total score is the average of the responses to the PIS items and ranges from 1 to 3 with lower scores indicating greater social connectedness.
|
Baseline, Month 1, Month 3
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Eun-Ok Im, PhD, MPH, Emory University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juni 2016
Primær fullføring (Faktiske)
9. juni 2021
Studiet fullført (Faktiske)
9. juni 2021
Datoer for studieregistrering
Først innsendt
14. juni 2016
Først innsendt som oppfylte QC-kriteriene
14. juni 2016
Først lagt ut (Anslag)
17. juni 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
29. juni 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
28. juni 2022
Sist bekreftet
1. juni 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB00117270
- R01CA203719-01 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Nei
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på American Cancer Society information on breast cancer
-
Washington University School of MedicineFullført